Cardio3 BioSciences Announces the Nomination of Three Co-principal Investigators for its CHART-2 Phase III Clinical Trial of C-Cure for the Treatment of Heart Failure will be Co-Principal Investigators of the phase III clinical trial CHART-2, authorized by the FDA in January : CARD ), a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today the appointment of its three Co-Principal Investigators for the CHART-2 study , authorized in CHART-2 is Cardio3 BioSciences' second Phase III trial for C-Cure , the first and only stem cell therapeutic using guided stem cells for the condition of congestive heart failure. C-Cure is currently in a Phase III clinical trial in .
http://ift.tt/1vMEIZu
http://ift.tt/1vMEIZu
No comments:
Post a Comment